

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product cand⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$5.76
Price0.00%
$0.00
$96.348m
Small
-
Premium
Premium
-3920375.3%
EBITDA Margin-3725080.7%
Net Profit Margin-3528478.2%
Free Cash Flow Margin$423.450k
-88.1%
1y CAGR-43.0%
3y CAGR-32.2%
5y CAGR-$6.109b
-40953.8%
1y CAGR-13668.4%
3y CAGR-10288.9%
5y CAGR-$1.24
-26.5%
1y CAGR+10.9%
3y CAGR-126.6%
5y CAGR$28.310b
$33.453b
Assets$5.142b
Liabilities-
Debt0.0%
-
Debt to EBITDA-$8.609b
-83577.6%
1y CAGR-27874.7%
3y CAGR-20925.8%
5y CAGR